A. Axitinib and erlotinib B. Sorafenib and lenvatinib C. Lenvatinib and imatinib D. Ibrutinib and sorafenib

A. Sorafenib and erlotinib B. Regorafenib and ibrutinib C. Regorafenib and cabozantinib D. Cabozantinib and ibrutinib

A. RAF (Rapidly accelerated fibroblast), VEGF (vascular endothelial growth factor), PDGF (platelet derived growth factor) B. FGFR (fibroblast growth factor receptor), BCR-ABL (Philadelphia chromosome), PDGF (platelet derived growth factor) C. HER-2 (human epidermal growth factor receptor), RAF (Rapidly accelerated fibroblast), JAK2 (Janus associated kinases), D. BTK (Bruton's tyrosine kinase), HER-2 (human epidermal growth factor receptor), RAF (Rapidly accelerated fibroblast)

A. Hepatitis C surface antigen, hepatitis C core antibody, hepatitis B surface antigen, hepatitis B core antibody B. Thyroid stimulating hormone (TSH), hepatitis C quantitative PCR, CBC with differential, toxicity assessment with focus on diarrhea, fatigue, skin reactions including hand-foot skin reaction C. Toxicity assessment only with focus on bleeding events, alopecia, abdominal pain, and fatigue D. CBC with differential, liver function tests, electrolytes, blood pressure, compliance, toxicity assessment with focus on diarrhea, fatigue, skin reactions including hand-foot skin reaction

A. Hand-foot skin reactions are common with this agent, and preventative measures include using moisturizer, avoid tight-fitting clothes, shoes and socks to minimize friction, remove calluses before start of regorafenib B. Take once a day with a low-fat meal, defined as fewer than 600 calories and less than 30% fat C. Constipation is a common side effect and can be managed with over the counter medications such as senna or polyethylene glycol 3350. Her goal should be 2 stools per day D. Diarrhea can occur and can be managed with loperamide (may need to be scheduled), and avoidance/minimization of triggers such as caffeine, milk-products, greasy and spicy foods

A. The STORM trial demonstrated that sorafenib greatly increased recurrence-free survival following surgical resection or local ablation of hepatocellular carcinoma B. Hand foot skin reactions from sorafenib or regorafenib are best treated with alcohol-based solutions, hot tub baths or saunas, and compression stockings C. Tyrosine kinase inhibitors are frequently metabolized through the CYP3A4 and this must be considered when choosing verapamil or diltiazem for the treatment of secondary hypertension D. Cabozantinib is currently FDA-approved for first-line systemic therapy of hepatocellular carcinoma